Consolidation of Clinical Trials Office within DSP
From: Reighley, Twila F
Sent: Wednesday, June 24, 2009 9:52 AM
Subject: Consolidation of the Clinical Trials Office into the Division of Sponsored Programs
The Office of the Vice President for Research (OVPR) reminds you that, as of July 1, 2009, all functions of the Clinical Trials Office (CTO) will be consolidated within the Division of Sponsored Programs (DSP). Former CTO staff members Jamie Chen, Linda Jones, and Kali Gray will relocate to the DSP office and continue to be directly involved in clinical trial issues; you may continue to direct general questions to (319)335-9575, and to reach specific staff members through the direct lines listed below. CTO Director Charlotte Talman has been appointed the Director of the UI Conflict of Interest in Research Office. We appreciate Ms. Talman's CTO leadership and will continue the dedication and focus she brought to processing and negotiating these agreements.
For the most part, this consolidation is expected to have very little impact on current procedures, but will mean the following changes:
- Beginning July 1, all corporate-sponsored clinical trial proposals and agreements must be routed to the Division of Sponsored Programs, 2 Gilmore Hall (GILH), rather than a separate, clinical trials office. This includes all clinical trial contract amendments as well, regardless of budget implications.
- Beginning July 1, non-monetary agreements related to clinical trials (e.g., confidentiality agreements and other agreements with no funding) are to be routed to the DSP using the MTA and Non-Monetary Agreement Routing Form available via UIRIS (with your HawkID).
The MTA and Non-Monetary Agreement Routing Form is an abbreviated format of the UI proposal routing form and is needed in order for DSP to review and provide institutional signature on such agreements.
The above changes are expected to bring consistency to the sponsored project routing procedure, so that clinical trial proposals and agreements will follow the same procedure applied to all other sponsored projects. Please note, however, that the facilities and administrative (F&A) rate applied to corporate-sponsored clinical trials will remain unchanged, at 25% of total direct costs (TDC).
We are expecting this transition to be relatively simple and beneficial to all concerned, and are available to assist you in any way possible. If at any point you have questions regarding the transition please contact Jamie Chen (335-9580), Linda Jones (353-5800), Kali Gray (335-9575), Wendy Beaver (335-2122) or me. Thank you.
Twila Fisher Reighley
Assistant Vice President for Research
Director, Division of Sponsored Programs
University of Iowa, 100 Gilmore Hall
Iowa City, Iowa 52242-1320